PIRS News and Press, Pieris Pharmaceuticals Inc. From 07/28/22

BOSTON, MA / ACCESSWIRE / July 28, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today ann...

BOSTON, MA / ACCESSWIRE / June 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announce...

The following slide deck was published by Pieris Pharmaceuticals, Inc. in conjunction with this event. For further details see: Pieris Pharmaceuticals (PIRS) Investor presentations - Slideshow

BOSTON, MA / ACCESSWIRE / May 18, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced that...

Pieris Pharmaceuticals, Inc (PIRS) Q1 2022 Earnings Conference Call May 11, 2022, 8:00 AM ET Company Participants Stephen S. Yoder – Chief Executive Officer, President, Director Thomas Bures – Senior Vice President, Chief Financial Officer Tim Demuth – Chief Medical Offic...

Pieris Pharmaceuticals press release (NASDAQ:PIRS): Q1 GAAP EPS of -$0.07 beats by $0.05. Revenue of $10.99M (-29.7% Y/Y) misses by $0.31M. "Pieris and our partners have made steady progress across the pipeline over the past quarter, and we are reiterating guidance on both cinrebafusp alfa ph...

Company To Host an Investor Conference Call On Wednesday, May 11, 2022 At 8:00 Am EDT BOSTON, MA / ACCESSWIRE / May 11, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ®...

Pieris Pharmaceuticals (NASDAQ:PIRS) is scheduled to announce Q1 earnings results on Wednesday, May 11th, before market open. The consensus EPS Estimate is -$0.19 (-171.4% Y/Y) and the consensus Revenue Estimate is $11.3M (-27.7% Y/Y). Over the last 3 months, EPS estimates have seen 1 upward ...

OTCQX:ADRNY, AGFY, BKSY, BLRX, DNUT, OTCPK:EONGY, EVGO, EXK, FLNG, FREY, FVRR, GMAB, ICL, INVZ, KRNT, LIVE, MCFT, OTCPK:NLLSF, NOMD, ONDS, PDSB, PFGC, PIRS, PRGO, PSFE, OTCPK:SPNX, TAK, TM, TRVN, WEN, WWR, WWW, XERS, YETI, ZOM For Seeking Alpha's full earnings season calendar, click here...

BOSTON, MA / ACCESSWIRE / May 4, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced...